vs
COMPASS MINERALS INTERNATIONAL INC（CMP）与UNITED THERAPEUTICS Corp（UTHR）财务数据对比。点击上方公司名可切换其他公司
UNITED THERAPEUTICS Corp的季度营收约是COMPASS MINERALS INTERNATIONAL INC的2.0倍（$790.2M vs $396.1M），UNITED THERAPEUTICS Corp净利率更高（46.1% vs 4.7%，领先41.4%），COMPASS MINERALS INTERNATIONAL INC同比增速更快（28.9% vs 7.4%），UNITED THERAPEUTICS Corp自由现金流更多（$173.3M vs $-59.8M），过去两年UNITED THERAPEUTICS Corp的营收复合增速更高（8.0% vs 4.3%）
指南针矿产国际是一家美国上市矿产企业，总部位于堪萨斯州欧弗兰帕克，是盐、氯化镁和硫酸钾等产品的领先生产商。公司面向北美和英国客户供应经处理与未经处理的散装道路除冰盐，同时向全球种植者提供植物营养产品，此外也生产民用除冰、水质调节产品及相关商用产品。
United Therapeutics是美国生物技术企业，专注开发包含异种移植在内的器官移植相关药物与技术，多款产品布局肺部疾病及器官制造赛道，双总部位于马里兰州银泉与北卡罗来纳州三角研究园，在美加多地设有研发及运营分支机构。
CMP vs UTHR — 直观对比
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $396.1M | $790.2M |
| 净利润 | $18.6M | $364.3M |
| 毛利率 | 16.0% | 86.9% |
| 营业利润率 | 9.2% | 45.1% |
| 净利率 | 4.7% | 46.1% |
| 营收同比 | 28.9% | 7.4% |
| 净利润同比 | 178.8% | 20.9% |
| 每股收益（稀释后） | $0.43 | $7.66 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $396.1M | $790.2M | ||
| Q3 25 | $227.5M | $799.5M | ||
| Q2 25 | $214.6M | $798.6M | ||
| Q1 25 | $494.6M | $794.4M | ||
| Q4 24 | $307.2M | $735.9M | ||
| Q3 24 | $208.8M | $748.9M | ||
| Q2 24 | $202.9M | $714.9M | ||
| Q1 24 | $364.0M | $677.7M |
| Q4 25 | $18.6M | $364.3M | ||
| Q3 25 | $-7.2M | $338.7M | ||
| Q2 25 | $-17.0M | $309.5M | ||
| Q1 25 | $-32.0M | $322.2M | ||
| Q4 24 | $-23.6M | $301.3M | ||
| Q3 24 | $-48.3M | $309.1M | ||
| Q2 24 | $-43.6M | $278.1M | ||
| Q1 24 | $-38.9M | $306.6M |
| Q4 25 | 16.0% | 86.9% | ||
| Q3 25 | 16.9% | 87.4% | ||
| Q2 25 | 19.2% | 89.0% | ||
| Q1 25 | 15.5% | 88.4% | ||
| Q4 24 | 11.2% | 89.7% | ||
| Q3 24 | 9.3% | 88.9% | ||
| Q2 24 | 16.1% | 89.1% | ||
| Q1 24 | 19.7% | 89.2% |
| Q4 25 | 9.2% | 45.1% | ||
| Q3 25 | 5.3% | 48.6% | ||
| Q2 25 | 7.4% | 45.6% | ||
| Q1 25 | -0.6% | 48.2% | ||
| Q4 24 | 0.2% | 48.6% | ||
| Q3 24 | -14.3% | 45.8% | ||
| Q2 24 | 2.9% | 44.7% | ||
| Q1 24 | -10.8% | 52.6% |
| Q4 25 | 4.7% | 46.1% | ||
| Q3 25 | -3.2% | 42.4% | ||
| Q2 25 | -7.9% | 38.8% | ||
| Q1 25 | -6.5% | 40.6% | ||
| Q4 24 | -7.7% | 40.9% | ||
| Q3 24 | -23.1% | 41.3% | ||
| Q2 24 | -21.5% | 38.9% | ||
| Q1 24 | -10.7% | 45.2% |
| Q4 25 | $0.43 | $7.66 | ||
| Q3 25 | — | $7.16 | ||
| Q2 25 | $-0.41 | $6.41 | ||
| Q1 25 | $-0.77 | $6.63 | ||
| Q4 24 | $-0.57 | $6.23 | ||
| Q3 24 | $-1.17 | $6.39 | ||
| Q2 24 | $-1.05 | $5.85 | ||
| Q1 24 | $-0.94 | $6.17 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $46.7M | $2.9B |
| 总债务越低越好 | $890.0M | — |
| 股东权益账面价值 | $260.5M | $7.1B |
| 总资产 | $1.5B | $7.9B |
| 负债/权益比越低杠杆越低 | 3.42× | — |
8季度趋势，按日历期对齐
| Q4 25 | $46.7M | $2.9B | ||
| Q3 25 | $59.7M | $2.8B | ||
| Q2 25 | $79.4M | $3.0B | ||
| Q1 25 | $49.5M | $3.3B | ||
| Q4 24 | $45.8M | $3.3B | ||
| Q3 24 | $20.2M | $3.3B | ||
| Q2 24 | $12.8M | $3.0B | ||
| Q1 24 | $38.3M | $2.7B |
| Q4 25 | $890.0M | — | ||
| Q3 25 | $839.8M | — | ||
| Q2 25 | $833.4M | — | ||
| Q1 25 | $807.6M | — | ||
| Q4 24 | $974.4M | — | ||
| Q3 24 | $921.2M | — | ||
| Q2 24 | $875.1M | — | ||
| Q1 24 | $877.2M | — |
| Q4 25 | $260.5M | $7.1B | ||
| Q3 25 | $234.1M | $6.6B | ||
| Q2 25 | $249.8M | $7.2B | ||
| Q1 25 | $236.5M | $6.8B | ||
| Q4 24 | $263.0M | $6.4B | ||
| Q3 24 | $316.6M | $6.1B | ||
| Q2 24 | $352.1M | $5.7B | ||
| Q1 24 | $400.4M | $5.3B |
| Q4 25 | $1.5B | $7.9B | ||
| Q3 25 | $1.5B | $7.4B | ||
| Q2 25 | $1.5B | $7.9B | ||
| Q1 25 | $1.5B | $7.7B | ||
| Q4 24 | $1.7B | $7.4B | ||
| Q3 24 | $1.6B | $7.1B | ||
| Q2 24 | $1.6B | $6.7B | ||
| Q1 24 | $1.7B | $6.5B |
| Q4 25 | 3.42× | — | ||
| Q3 25 | 3.59× | — | ||
| Q2 25 | 3.34× | — | ||
| Q1 25 | 3.41× | — | ||
| Q4 24 | 3.70× | — | ||
| Q3 24 | 2.91× | — | ||
| Q2 24 | 2.49× | — | ||
| Q1 24 | 2.19× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-37.0M | $346.2M |
| 自由现金流经营现金流 - 资本支出 | $-59.8M | $173.3M |
| 自由现金流率自由现金流/营收 | -15.1% | 21.9% |
| 资本支出强度资本支出/营收 | 5.8% | 21.9% |
| 现金转化率经营现金流/净利润 | -1.99× | 0.95× |
| 过去12个月自由现金流最近4个季度 | $94.1M | $1.0B |
8季度趋势，按日历期对齐
| Q4 25 | $-37.0M | $346.2M | ||
| Q3 25 | $-6.9M | $562.1M | ||
| Q2 25 | $21.8M | $191.7M | ||
| Q1 25 | $186.9M | $461.2M | ||
| Q4 24 | $-4.1M | $341.2M | ||
| Q3 24 | $-12.7M | $377.2M | ||
| Q2 24 | $-6.8M | $232.2M | ||
| Q1 24 | $86.2M | $376.5M |
| Q4 25 | $-59.8M | $173.3M | ||
| Q3 25 | $-22.8M | $351.6M | ||
| Q2 25 | $3.8M | $129.5M | ||
| Q1 25 | $172.9M | $386.3M | ||
| Q4 24 | $-25.9M | $254.5M | ||
| Q3 24 | $-33.6M | $300.7M | ||
| Q2 24 | $-21.5M | $187.1M | ||
| Q1 24 | $56.2M | $338.3M |
| Q4 25 | -15.1% | 21.9% | ||
| Q3 25 | -10.0% | 44.0% | ||
| Q2 25 | 1.8% | 16.2% | ||
| Q1 25 | 35.0% | 48.6% | ||
| Q4 24 | -8.4% | 34.6% | ||
| Q3 24 | -16.1% | 40.2% | ||
| Q2 24 | -10.6% | 26.2% | ||
| Q1 24 | 15.4% | 49.9% |
| Q4 25 | 5.8% | 21.9% | ||
| Q3 25 | 7.0% | 26.3% | ||
| Q2 25 | 8.4% | 7.8% | ||
| Q1 25 | 2.8% | 9.4% | ||
| Q4 24 | 7.1% | 11.8% | ||
| Q3 24 | 10.0% | 10.2% | ||
| Q2 24 | 7.2% | 6.3% | ||
| Q1 24 | 8.2% | 5.6% |
| Q4 25 | -1.99× | 0.95× | ||
| Q3 25 | — | 1.66× | ||
| Q2 25 | — | 0.62× | ||
| Q1 25 | — | 1.43× | ||
| Q4 24 | — | 1.13× | ||
| Q3 24 | — | 1.22× | ||
| Q2 24 | — | 0.83× | ||
| Q1 24 | — | 1.23× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CMP
| Highway Deicing Salt | $210.8M | 53% |
| Consumer Industrial Salt | $120.7M | 30% |
| Plant Nutrition | $60.8M | 15% |
| Transferred Over Time | $2.8M | 1% |
| Other | $1.0M | 0% |
UTHR
| Tyvaso DPI | $338.6M | 43% |
| Remodulin | $128.0M | 16% |
| Nebulized Tyvaso | $125.7M | 16% |
| Orenitram | $121.2M | 15% |
| Unituxin | $62.3M | 8% |
| Adcirca | $7.8M | 1% |
| Other | $6.6M | 1% |
